Discontinuation of antiviral prophylaxis correlates with high prevalence of hepatitis B virus (HBV) reactivation in rheumatoid arthritis patients with HBV carrier state: A real-world clinical practice

BMC Musculoskeletal Disorders

Volumn 15, Issue 1, 2015, Pages

  Mo, Ying Qian ^a   Liang, An Qi ^a   Ma, Jian Da ^a   Chen, Le Feng ^a   Zheng, Dong Hui ^a   Schumacher, H Ralph ^b   Dai, Lie ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Disease modifying antirheumatic drugs; Hepatitis B virus; Rheumatoid arthritis

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIVIRUS AGENT; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ENTECAVIR; HEPATITIS B(E) ANTIGEN; HYDROXYCHLOROQUINE; INFLIXIMAB; LAMIVUDINE; LEFLUNOMIDE; METHOTREXATE; SALAZOSULFAPYRIDINE; TENOFOVIR; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; VIRUS DNA;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL PRACTICE; DECOMPENSATED LIVER CIRRHOSIS; DRUG COST; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HEPATITIS B; HUMAN; INFECTION PREVENTION; LOW DRUG DOSE; MALE; MEDICAL HISTORY; OUTCOME ASSESSMENT; RHEUMATOID ARTHRITIS; RISK FACTOR; SEROCONVERSION; VIRUS REACTIVATION; ARTHRITIS, RHEUMATOID; DRUG EFFECTS; HEPATITIS B VIRUS; HETEROZYGOTE; MIDDLE AGED; PHYSIOLOGY; POST EXPOSURE PROPHYLAXIS; PREVALENCE; PROCEDURES; TRENDS; VIRUS ACTIVATION;

ADULT; ANTIVIRAL AGENTS; ARTHRITIS, RHEUMATOID; CARRIER STATE; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; MALE; MIDDLE AGED; POST-EXPOSURE PROPHYLAXIS; PREVALENCE; VIRUS ACTIVATION;

EID: 84924264334     PISSN: None     EISSN: 14712474     Source Type: Journal    
DOI: 10.1186/1471-2474-15-449     Document Type: Article

References (29)

1. Liang X, Bi S, Yang W, Wang L, Cui G, Cui F, Zhang Y, Liu J, Gong X, Chen Y, Wang F, Zheng H, Wang F, Guo J, Jia Z, Ma J, Wang H, Luo H, Li L, Jin S, Hadler SC, Wang Y: Epidemiological sero survey of hepatitis B in China- declining HBV prevalence due to hepatitis B vaccination. Vaccine 2009, 27:6550-6557.
2. Liaw YF, Chu CM: Hepatitis B virus infection. Lancet 2009, 373:582-592.
3. Zou CJ, Zhu LJ, Li YH, Mo YQ, Zheng DH, Ma JD, Ou-Yang X, Pessler F, Dai L: The association between hepatitis B virus infection and disease activity, synovitis, or joint destruction in rheumatoid arthritis. Clin Rheumatol 2013, 32:787-795.
4. Vassilopoulos D, Calabrese LH: Management of rheumatic disease with comorbid HBV or HCV infection. Nat Rev Rheumatol 2012, 8:348-357.
5. Liaw YF, Kao JH, Piratvisuth T, Chan LY, Chien RN, Liu CJ, Gane E, Locarnini S, Lim SG, Han KH, Amarapurkar, Cooksley G, Jafri W, Mohamed R, Hou JL, Chuang WL, Lesmana LA, Sollano JD, Suh DJ, Omata M: Asian-Pacific consensus statement on the management of chronic hepatitis B: A 2012 update. Hepatol Int 2012, 6:531-561.
6. Lok AS, McMahon BJ: Chronic hepatitis B: update 2009. Hepatology 2009, 50:661-662.
7. European Association For The Study Of The Liver: EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012, 57:167-185.
8. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, Paulus HE, Mudano A, Pisu M, Elkins-Melton M, Outman R, Allison JJ, Suarez Almazor M, Bridges SL Jr, Chatham WW, Hochberg M, MacLean C, Mikuls T, Moreland LW, O'Dell J, Turkiewicz AM, Furst DE, American College of Rheumatology: American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying anti rheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008, 59:762-784.
9. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, Moreland LW, O'Dell J, Winthrop KL, Beukelman T, Bridges SL Jr, Chatham WW, Paulus HE, Suarez-Almazor M, Bombardier C, Dougados M, Khanna D, King CM, Leong AL, Matteson EL, Schousboe JT, Moynihan E, Kolba KS, Jain A, Volkmann ER, Agrawal H, Bae S, Mudano AS, Patkar NM, Saag KG: 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying anti rheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012, 64:625-639.
10. Yeo W, Chan PK, Zhong S, Ho WM, Steinberg JL, Tam JS, Hui P, Leung NW, Zee B, Johnson PJ: Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: A prospective study of 626 patients with identification of risk factors. J Med Virol 2000, 62:299-307.
11. Hwang JP, Lok AS: Management of patients with hepatitis B who require immunosuppressive therapy. Nat Rev Gastroenterol Hepatol 2014, 11:209-219.
12. Liaw YF: Natural history of chronic hepatitis B virus infection and longterm outcome under treatment. Liver Int 2009, 29(Suppl 1):100-107.
13. Tai DI, Lin SM, Sheen IS, Chu CM, Lin DY, Liaw YF: Long-term outcome of hepatitis B e antigen-negative hepatitis B surface antigen carriers in relation to changes of alanine amino transferase levels over time. Hepatology 2009, 49:1859-1867.
14. Malespin M, Wong S, Siqueira F, Luc B, Ravaee B, Vainder C, Cotler SJ: Barriers to treatment of hepatitis B in an urban Chinatown community. J Clin Gastroenterol 2012, 46:e66-e70.
15. Dienstag JL: Hepatitis B virus infection. N Engl J Med 2008, 359:1486-1500.
16. Ryu HH, Lee EY, Shin K, Choi IA, Lee YJ, Yoo B, Park MC, Park YB, Bae SC, Yoo WH, Kim SI, Lee EB, Song YW: Hepatitis B virus reactivation in rheumatoid arthritis and ankylosing spondylitis patients treated with anti-TNFα agents: A retrospective analysis of 49 cases. Clin Rheumatol 2012, 31:931-936.
17. Lim SG, Wai CT, Rajnakova A, Kajiji T, Guan R: Fatal hepatitis B reactivation following discontinuation of nucleoside analogues for chronic hepatitis B. Gut 2002, 51:597-599.
18. Hoppe-Seyler K, Sauer P, Lohrey C, Hoppe-Seyler F: The inhibitors of nucleotide biosynthesis leflunomide, FK778, and mycophenolic acid activate hepatitis B virus replication in vitro. Hepatology 2012, 56:9-16.
19. Emery P, Breedveld FC, Lemmel EM, Kaltwasser JP, Dawes PT, Gömör B, Van Den Bosch F, Nordström D, Bjorneboe O, Dahl R, Horslev-Petersen K, Rodriguez De La Serna A, Molloy M, Tikly M, Oed C, Rosenburg R, Loew- Friedrich I: A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology (Oxford) 2000, 39:655-665.
20. Xuan D, Yu Y, Shao L, Wang J, Zhang W, Zou H: Hepatitis reactivation in patients with rheumatic diseases after immunosuppressive therapy-a report of long-term follow-up of serial cases and literature review. Clin Rheumatol 2014, 33:577-586.
21. Gwak GY, Koh KC, Kim HY: Fatal hepatic failure associated with hepatitis B virus reactivation in a hepatitis B surface antigen-negative patient with rheumatoid arthritis receiving low dose methotrexate. Clin Exp Rheumatol 2007, 25:888-889.
22. Ostuni P, Botsios C, Punzi L, Sfriso P, Todesco S: Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate. Ann Rheum Dis 2003, 62:686-687.
23. Ito S, Nakazono K, Murasawa A, Mita Y, Hata K, Saito N, Kikuchi M, Yoshida K, Nakano M, Gejyo F: Development of fulminant hepatitis B (precore variant mutant type) after the discontinuation of low-dose methotrexate therapy in a rheumatoid arthritis patient. Arthritis Rheum 2001, 44:339-342.
24. Smolen JS, Landewé R, Breedveld FC, Buch M, Burmester G, Dougados M, Emery P, Gaujoux-Viala C, Gossec L, Nam J, Ramiro S, Winthrop K, de Wit M, Aletaha D, Betteridge N, Bijlsma JW, Boers M, Buttgereit F, Combe B, Cutolo M, Damjanov N, Hazes JM, Kouloumas M, Kvien TK, Mariette X, Pavelka K, van Riel PL, Rubbert-Roth A, Scholte-Voshaar M, Scott DL, Sokka-Isler T, Wong JB, van der Heijde D: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying anti rheumatic drugs: 2013 update. Ann Rheum Dis 2014, 73:492-509.
25. Tan J, Zhou J, Zhao P, Wei J: Prospective study of HBV reactivation risk in rheumatoid arthritis patients who received conventional diseasemodifying anti rheumatic drugs. Clin Rheumatol 2012, 31:1169-1175.
26. Costa L, Caso F, Atteno M, Giannitti C, Spadaro A, Ramonda R, Vezzù M, Del Puente A, Morisco F, Fiocco U, Galeazzi M, Punzi L, Scarpa R: Long-term safety of anti-TNF-α in PsA patients with concomitant HCV infection: A retrospective observational multicenter study on 15 patients. Clin Rheumatol 2014, 33:273-276.
27. Giannitti C, Fineschi I, Frediani B, Fioravanti A, Galeazzi M: Efficacy and safety of tocilizumab combined with cyclosporine A in a patient with rheumatoid arthritis and concomitant chronic hepatitis C virus infection. Clin Exp Rheumatol 2013, 31:816.
28. Galeazzi M, Bellisai F, Giannitti C, Manganelli S, Morozzi G, Sebastiani GD: Safety of cyclosporin A in HCV-infected patients: experience with cyclosporin A in patients affected byrheumatological disorders and concomitant HCV infection. Ann N Y Acad Sci 2007, 1110:544-549.
29. Giannitti C, Sebastiani GD, Manganelli S, Galeazzi M: Safety of anti-tumor necrosis factor agents in rheumatic potential carriers of occult hepatitis B virus. J Rheumatol 2011, 38:780-781.